title: Pathological complete response induced by the combination therapy of S-1 and 24-h infusion of cisplatin in two cases initially diagnosed as inoperable advanced gastric cancer.
abstract: We report on two patients, successfully treated by the combination therapy of S-1 and 24-h infusion of cisplatin (CDDP), who were initially diagnosed with unresectable stage 4 advanced gastric cancer. Each patient had a very good clinical response and underwent curative gastrectomy after completion of 14 and 10 courses of S-1/CDDP chemotherapy, respectively. A microscopically detailed examination of surgically obtained specimens showed the complete disappearance of malignant cells in the two cases. S-1/CDDP combination therapy can, therefore, be highly active in incurable advanced gastric carcinoma.
authors.affiliation: Department of Medical Oncology, Nagoya Memorial Hospital, Nagoya 468-8520, Japan. kina@hospy.or.jp
authors.forename: Kenji
authors.initials: K
authors.lastname: Ina
authors.forename: Takae
authors.initials: T
authors.lastname: Kataoka
authors.forename: Yuuki
authors.initials: Y
authors.lastname: Takeuchi
authors.forename: Tomoki
authors.initials: T
authors.lastname: Fukuoka
authors.forename: Takaya
authors.initials: T
authors.lastname: Miwa
authors.forename: Tomoko
authors.initials: T
authors.lastname: Nishio
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Furuta
authors.forename: Ayako
authors.initials: A
authors.lastname: Masaki
authors.forename: Fumiko
authors.initials: F
authors.lastname: Mori
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kayukawa
authors.forename: Seiji
authors.initials: S
authors.lastname: Nagao
authors.forename: Takafumi
authors.initials: T
authors.lastname: Ando
authors.forename: Hidemi
authors.initials: H
authors.lastname: Goto
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D011379:Prognosis; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin